Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: A replication study

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Freburger, Janet K ^a   Ellis, Alan R ^a   Kshirsagar, Abhijit V ^b   Wang, Lily ^a   Brookhart, M Alan ^a,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

Author keywords

Anemia management; Hemodialysis; Intravenous iron

Indexed keywords

ANTIBIOTIC AGENT; IRON;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BOLUS INJECTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CATHETERIZATION; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART INFARCTION; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; INFECTION; IRON THERAPY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT SAFETY; PNEUMONIA; PROGNOSIS; REPLICATION STUDY; RETROSPECTIVE STUDY; SEPSIS; TREATMENT OUTCOME; VASCULAR ACCESS; ADVERSE EFFECTS; AGED; CATHETER-RELATED INFECTIONS; COHORT ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION; INDWELLING CATHETER; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; RENAL REPLACEMENT THERAPY; TIME;

AGED; CATHETER-RELATED INFECTIONS; CATHETERS, INDWELLING; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IRON; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84908135239     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-154     Document Type: Article

References (25)

1. Besarab A, Kaiser JW, Frinak S: A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999, 34(1):21-28.
2. Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB: Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001, 37(2):300-307.
3. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007, 18(3):975-984.
4. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA: The comparative short-term effectiveness of iron dosing and formulations in U.S. hemodialysis patients. Am J Med 2013, 126(6):541. e541-541.e514.
5. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355(20):2071-2084.
6. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, Mcgill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361(21):2019-2032.
7. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355(20):2085-2098.
8. Brewster UC: Intravenous iron therapy in end-stage renal disease. Semin Dial 2006, 19(4):285-290.
9. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000, 15(11):1827-1834.
10. Brewster UC, Perazella MA: Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial 2004, 17(1):57-60.
11. Bullen JJ, Rogers HJ, Spalding PB, Ward CG: Iron and infection: the heart of the matter. FEMS Immunol Med Microbiol 2005, 43 (3):325-330.
12. Collins AJ, Ebben J, Ma JZ, Xia H: Iron dosing patterns and mortality [abstract]. J Am Soc Nephrol 1998, 9:250A.
13. Halliwell B, Gutteridge JM: Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984, 219(1):1-14.
14. Martin-Malo A, Merino A, Carracedo J, Alvarez-Lara MA, Ojeda R, Soriano S, Crespo R, Ramirez R, Aljama P: Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 2012, 27(6):2465-2471.
15. Sevanian A, Hochstein P: Mechanisms and consequences of lipid peroxidation in biological systems. Annu Rev Nutr 1985, 5:365-390.
16. Berliner JA, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996, 20(5):707-727.
17. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002, 62(5):1524-1538.
18. Brookhart MA, Freburger JK, Ellis K, Wang L, Winkelmayer WC, Kshirsagar AV: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Nephrol Soc 2013, 24 (7):1151-1158.
19. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA: The comparative short-term cardiovascular safety of intravenous iron dosing in hemodialysis patients. PLOS One 2013, 8(11):e78930.
20. U.S. Renal Data System Coordinating Center: Researcher's Guide to the USRDS Database, 2011. Bethesda, MD: National Institutes of Health, NIDDK; 2012.
21. Elixhauser A, Steiner C, Harris DR, Coffey RM: Comorbidity measures for use with administrative data. Med Care 1998, 36(1):8-27.
22. Xie X, Strickler HD, Xue X: Additive hazard regression models: an application to the natural history of human papillomavirus. Comput Math Methods Med 2013, 2013:796270.
23. Lin DY, Wei LJ: The robust inference for the proportional hazards model. J Am Stat Assoc 1989, 84:1074-1078.
24. Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology 2000, 11(5):550-560.
25. Hernan MA, Brumback B, Robins JM: Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000, 11(5):561-570.